Skip to main content
. 2020 Dec 15;17(4):1002–1013. doi: 10.20892/j.issn.2095-3941.2020.0089

Figure 5.

Figure 5

Potential future treatment approaches in HR-mut GC. Homologous recombination deficiency (HRD); tumor mutational burden (TMB); somatic copy number alterations (SCNAs); interferon-gamma (IFN-γ); poly-ADP ribose polymerase inhibitors (PARPi); immune checkpoint inhibitors (ICIs).